PhRMA's Scott LaGanga discusses the expanding influence of state policymaking on drug pricing, PBM reform, and efforts to translate policy changes into lower out-of-pocket costs for patients.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.